A novel triple therapy shows promising signs of efficacy in localised lung cancer
The MATISSE study, presented by Professor Fabrice Barlesi, CEO of Gustave Roussy, during a plenary session on clinical trials at the AACR congress, evaluated the addition of a new molecule to the therapeutically validated combination already used for certain patients with non-small cell lung cancer. This novel triple therapy has demonstrated initial promising clinical effects.